You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameBotulinum Toxin Type A
Accession NumberDB00083  (BTD00092, BIOD00092)
TypeBiotech
GroupsApproved, Investigational
DescriptionPurified botulinum toxin from Clostridium botulinum, purified from culture via dialysis and acid precipitation.
Protein structureDb00083
Related Articles
Protein chemical formulaC6760H10447N1743O2010S32
Protein average weight149322.7 Da
Sequences
>Botulinum Toxin Type A Sequence
MPFVNKQFNYKDPVNGVDIAYIKIPNVGQMQPVKAFKIHNKIWVIPERDTFTNPEEGDLN
PPPEAKQVPVSYYDSTYLSTDNEKDNYLKGVTKLFERIYSTDLGRMLLTSIVRGIPFWGG
STIDTELKVIDTNCINVIQPDGSYRSEELNLVIIGPSADIIQFECKSFGHEVLNLTRNGY
GSTQYIRFSPDFTFGFEESLEVDTNPLLGAGKFATDPAVTLAHELIHAGHRLYGIAINPN
RVFKVNTNAYYEMSGLEVSFEELRTFGGHDAKFIDSLQENEFRLYYYNKFKDIASTLNKA
KSIVGTTASLQYMKNVFKEKYLLSEDTSGKFSVDKLKFDKLYKMLTEIYTEDNFVKFFKV
LNRKTYLNFDKAVFKINIVPKVNYTIYDGFNLRNTNLAANFNGQNTEINNMNFTKLKNFT
GLFEFYKLLCVRGIITSKTKSLDKGYNKALNDLCIKVNNWDLFFSPSEDNFTNDLNKGEE
ITSDTNIEAAEENISLDLIQQYYLTFNFDNEPENISIENLSSDIIGQLELMPNIERFPNG
KKYELDKYTMFHYLRAQEFEHGKSRIALTNSVNEALLNPSRVYTFFSSDYVKKVNKATEA
AMFLGWVEQLVYDFTDETSEVSTTDKIADITIIIPYIGPALNIGNMLYKDDFVGALIFSG
AVILLEFIPEIAIPVLGTFALVSYIANKVLTVQTIDNALSKRNEKWDEVYKYIVTNWLAK
VNTQIDLIRKKMKEALENQAEATKAIINYQYNQYTEEEKNNINFNIDDLSSKLNESINKA
MININKFLNQCSVSYLMNSMIPYGVKRLEDFDASLKDALLKYIYDNRGTLIGQVDRLKDK
VNNTLSTDIPFQLSKYVDNQRLLSTFTEYIKNIINTSILNLRYESNHLIDLSRYASKINI
GSKVNFDPIDKNQIQLFNLESSKIEVILKNAIVYNSMYENFSTSFWIRIPKYFNSISLNN
EYTIINCMENNSGWKVSLNYGEIIWTLQDTQEIKQRVVFKYSQMINISDYINRWIFVTIT
NNRLNNSKIYINGRLIDQKPISNLGNIHASNNIMFKLDGCRDTHRYIWIKYFNLFDKELN
EKEIKDLYDNQSNSGILKDFWGDYLQYDKPYYMLNLYDPNKYVDVNNVGIRGYMYLKGPR
GSVMTTNIYLNSSLYRGTKFIIKKYASGNKDNIVRNNDRVYINVVVKNKEYRLATNASQA
GVEKILSALEIPDVGNLSQVVVMKSKNDQGITNKCKMNLQDNNGNDIGFIGFHQFNNIAK
LVASNWYNRQIERSSRTLGCSWEFIPVDDGWGERPL
Download FASTA Format
Synonyms
AbobotulinumtoxinA
BoNT/A
Bontoxilysin A
Botulinum neurotoxin type A precursor
BTX-A
IncobotulinumtoxinA
OnabotulinumtoxinA
External IDs Not Available
Product Ingredients Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
BotoxInjection, powder, lyophilized, for solution100 [USP'U]/1Intradermal; IntramuscularAllergan1989-12-15Not applicableUs
BotoxInjection, powder, lyophilized, for solution200 [USP'U]/1Intradermal; IntramuscularAllergan2010-01-11Not applicableUs
BotoxPowder, for solution100 unitIntramuscularAllergan1992-12-31Not applicableCanada
Botox CosmeticPowder, for solution100 unitIntramuscularAllergan2001-05-07Not applicableCanada
Botox CosmeticInjection, powder, lyophilized, for solution50 [USP'U]/1IntramuscularAllergan2008-07-15Not applicableUs
Botox CosmeticInjection, powder, lyophilized, for solution100 [USP'U]/1IntramuscularAllergan2008-05-20Not applicableUs
DysportInjection, powder, lyophilized, for solution500 U/1IntramuscularIpsen Biopharmaceuticals, Inc.2009-11-02Not applicableUs
DysportInjection, powder, lyophilized, for solution300 U/1IntramuscularGalderma2009-11-02Not applicableUs
DysportInjection, powder, lyophilized, for solution300 U/1IntramuscularIpsen Biopharmaceuticals, Inc.2009-11-02Not applicableUs
Dysport AestheticPowder, for solution300 unitIntramuscularIpsen Biopharm Limited2013-02-19Not applicableCanada
Dysport TherapeuticPowder, for solution500 unitIntramuscularIpsen Biopharm Limited2017-02-27Not applicableCanada
Dysport TherapeuticPowder, for solution300 unitIntramuscularIpsen Biopharm Limited2017-02-27Not applicableCanada
XeominInjection, powder, lyophilized, for solution100 [USP'U]/1IntramuscularMerz Pharmaceuticals2010-09-01Not applicableUs
XeominInjection, powder, lyophilized, for solution50 [USP'U]/1IntramuscularMerz North America, Inc.2011-08-01Not applicableUs
XeominInjection, powder, lyophilized, for solution200 [USP'U]/1IntramuscularMerz Pharmaceuticals2015-11-20Not applicableUs
XeominPowder, for solution100 unitIntramuscularMerz Pharmaceuticals2009-07-21Not applicableCanada
XeominInjection, powder, lyophilized, for solution100 [USP'U]/1IntramuscularMerz Pharmaceuticals2010-09-01Not applicableUs
XeominPowder, for solution50 unitIntramuscularMerz Pharmaceuticals2012-07-04Not applicableCanada
XeominInjection, powder, lyophilized, for solution50 [USP'U]/1IntramuscularMerz Pharmaceuticals2010-09-01Not applicableUs
XeominInjection, powder, lyophilized, for solution50 [USP'U]/1IntramuscularMerz Pharmaceuticals2010-09-01Not applicableUs
XeominInjection, powder, lyophilized, for solution100 [USP'U]/1IntramuscularMerz North America, Inc.2011-08-01Not applicableUs
XeominInjection, powder, lyophilized, for solution50 [USP'U]/1IntramuscularMerz North America, Inc.2011-08-01Not applicableUs
Xeomin CosmeticPowder, for solution100 unitIntramuscularMerz Pharmaceuticals2012-07-05Not applicableCanada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Categories
UNIIE211KPY694
CAS number93384-43-1
Pharmacology
IndicationFor the treatment of cervical dystonia in adults to decrease the severity of abnormal head position and neck pain associated with cervical dystonia. Also for the treatment of severe primary axillary hyperhidrosis that is inadequately managed with topical agents and for the treatment of strabismus and blepharospasm associated with dystonia, including benign essential blepharospasm or VII nerve disorders in patients 12 years of age and above. Also used cosmetically to temporarily improve the appearance of moderate-to-severe frown lines between the eyebrows (glabellar lines) as well as for the treatment of excessive underarm sweating.
Structured Indications
PharmacodynamicsA 150 kDa neurotoxic protein produced from fermentation of Hall strain Clostridium botulinum type A grown in a medium containing casein hydrolysate, glucose and yeast extract. It is purified from the culture solution by dialysis and a series of acid precipitations to a complex consisting of the neurotoxin, and several accessory proteins. Botulinum Toxin Type A is not expected to be present in the peripheral blood at measurable levels following IM or intradermal injection at the recommended doses. The recommended quantities of neurotoxin administered at each treatment session are not expected to result in systemic, overt distant clinical effects, i.e. muscle weakness, in patients without other neuromuscular dysfunction. However, sub-clinical systemic effects have been shown by single-fiber electromyography after IM doses of botulinum toxins appropriate to produce clinically observable local muscle weakness.
Mechanism of actionBotulinum Toxin Type A blocks neuromuscular transmission by binding to acceptor sites on motor or sympathetic nerve terminals, entering the nerve terminals, and inhibiting the release of acetylcholine. This inhibition occurs as the neurotoxin cleaves SNAP-25, a protein integral to the successful docking and release of acetylcholine from vesicles situated within nerve endings.
TargetKindPharmacological actionActionsOrganismUniProt ID
Synaptosomal-associated protein 25Proteinyes
inhibitor
HumanP60880 details
Rho-related GTP-binding protein RhoBProteinunknownNot AvailableHumanP62745 details
Related Articles
AbsorptionThe chemical complexity of Botulinum Toxin Type A combined with its extreme potency limits the opportunity to study its pharmacokinetic profile in humans. Therefore, no human pharmacokinetic studies have been performed. Botulinum Toxin Type A is injected directly into the target organ, a skeletal muscle. Thus, bioavailability of the intravenous or oral route is not of clinical relevance.
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityBased on toxicological studies, it has been estimated that the human LD50 by injection is approximately 2800 Units, equivalent to 28 individual vials of BOTOX (Botulinum Toxin Type A) Purified Neurotoxin Complex (100 Units) for a 70 kg adult. When injected intramuscularly, Botulinum Toxin Type A has been shown to be teratogenic or to have embryocidal effects in some animal species.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
AclarubicinAclarubicin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.Investigational
AclidiniumAclidinium may increase the anticholinergic activities of Botulinum Toxin Type A.Approved
AmikacinAmikacin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.Approved, Vet Approved
AmrubicinAmrubicin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.Approved, Investigational
Anisotropine MethylbromideAnisotropine Methylbromide may increase the anticholinergic activities of Botulinum Toxin Type A.Approved
annamycinannamycin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.Investigational
ApramycinApramycin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.Experimental, Vet Approved
ArbekacinArbekacin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.Approved
Atracurium besylateBotulinum Toxin Type A may increase the neuromuscular blocking activities of Atracurium besylate.Approved
AtropineAtropine may increase the anticholinergic activities of Botulinum Toxin Type A.Approved, Vet Approved
BenactyzineBenactyzine may increase the anticholinergic activities of Botulinum Toxin Type A.Withdrawn
BenzatropineBenzatropine may increase the anticholinergic activities of Botulinum Toxin Type A.Approved
BiperidenBiperiden may increase the anticholinergic activities of Botulinum Toxin Type A.Approved
Botulinum Toxin Type BBotulinum Toxin Type A may increase the adverse neuromuscular activities of Botulinum Toxin Type B.Approved
ChlorphenoxamineChlorphenoxamine may increase the anticholinergic activities of Botulinum Toxin Type A.Withdrawn
Cisatracurium besylateBotulinum Toxin Type A may increase the neuromuscular blocking activities of Cisatracurium besylate.Approved
CyclopentolateCyclopentolate may increase the anticholinergic activities of Botulinum Toxin Type A.Approved
DarifenacinDarifenacin may increase the anticholinergic activities of Botulinum Toxin Type A.Approved, Investigational
DaunorubicinDaunorubicin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.Approved
DecamethoniumBotulinum Toxin Type A may increase the neuromuscular blocking activities of Decamethonium.Approved
DesloratadineDesloratadine may increase the anticholinergic activities of Botulinum Toxin Type A.Approved, Investigational
DexetimideDexetimide may increase the anticholinergic activities of Botulinum Toxin Type A.Withdrawn
DicyclomineDicyclomine may increase the anticholinergic activities of Botulinum Toxin Type A.Approved
DihydrostreptomycinDihydrostreptomycin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.Vet Approved
Domoic AcidBotulinum Toxin Type A may increase the neuromuscular blocking activities of Domoic Acid.Experimental
Doxacurium chlorideBotulinum Toxin Type A may increase the neuromuscular blocking activities of Doxacurium chloride.Approved
DoxorubicinDoxorubicin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.Approved, Investigational
EpirubicinEpirubicin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.Approved
EthopropazineEthopropazine may increase the anticholinergic activities of Botulinum Toxin Type A.Approved
FesoterodineFesoterodine may increase the anticholinergic activities of Botulinum Toxin Type A.Approved
FramycetinFramycetin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.Approved
Gallamine TriethiodideBotulinum Toxin Type A may increase the neuromuscular blocking activities of Gallamine Triethiodide.Approved
GeneticinGeneticin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.Experimental
GentamicinGentamicin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.Approved, Vet Approved
GENTAMICIN C1AGENTAMICIN C1A may increase the neuromuscular blocking activities of Botulinum Toxin Type A.Experimental
GlycopyrroniumGlycopyrronium may increase the anticholinergic activities of Botulinum Toxin Type A.Approved, Investigational, Vet Approved
HexamethoniumHexamethonium may increase the anticholinergic activities of Botulinum Toxin Type A.Experimental
HomatropineHomatropine may increase the anticholinergic activities of Botulinum Toxin Type A.Approved
Hygromycin BHygromycin B may increase the neuromuscular blocking activities of Botulinum Toxin Type A.Vet Approved
HyoscyamineHyoscyamine may increase the anticholinergic activities of Botulinum Toxin Type A.Approved
IdarubicinIdarubicin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.Approved
INNO-206INNO-206 may increase the neuromuscular blocking activities of Botulinum Toxin Type A.Investigational
Ipratropium bromideIpratropium bromide may increase the anticholinergic activities of Botulinum Toxin Type A.Approved
KanamycinKanamycin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.Approved, Vet Approved
MecamylamineMecamylamine may increase the anticholinergic activities of Botulinum Toxin Type A.Approved
MethanthelineMethantheline may increase the anticholinergic activities of Botulinum Toxin Type A.Approved
MetixeneMetixene may increase the anticholinergic activities of Botulinum Toxin Type A.Approved
MetocurineBotulinum Toxin Type A may increase the neuromuscular blocking activities of Metocurine.Approved
Metocurine IodideBotulinum Toxin Type A may increase the neuromuscular blocking activities of Metocurine Iodide.Withdrawn
MetrizamideMetrizamide may increase the neuromuscular blocking activities of Botulinum Toxin Type A.Approved
MivacuriumBotulinum Toxin Type A may increase the neuromuscular blocking activities of Mivacurium.Approved
N-butylscopolammonium bromideN-butylscopolammonium bromide may increase the anticholinergic activities of Botulinum Toxin Type A.Vet Approved
NeamineNeamine may increase the neuromuscular blocking activities of Botulinum Toxin Type A.Experimental
NeomycinNeomycin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.Approved, Vet Approved
NeosaxitoxinBotulinum Toxin Type A may increase the neuromuscular blocking activities of Neosaxitoxin.Investigational
NetilmicinNetilmicin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.Approved
NVA237NVA237 may increase the anticholinergic activities of Botulinum Toxin Type A.Investigational
OrphenadrineOrphenadrine may increase the anticholinergic activities of Botulinum Toxin Type A.Approved
OxybutyninOxybutynin may increase the anticholinergic activities of Botulinum Toxin Type A.Approved, Investigational
OxyphenoniumOxyphenonium may increase the anticholinergic activities of Botulinum Toxin Type A.Approved
PancuroniumBotulinum Toxin Type A may increase the neuromuscular blocking activities of Pancuronium.Approved
ParomomycinParomomycin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.Approved, Investigational
PentoliniumPentolinium may increase the anticholinergic activities of Botulinum Toxin Type A.Approved
PipecuroniumBotulinum Toxin Type A may increase the neuromuscular blocking activities of Pipecuronium.Approved
PirarubicinPirarubicin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.Investigational
PirenzepinePirenzepine may increase the anticholinergic activities of Botulinum Toxin Type A.Approved
PlicamycinPlicamycin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.Approved, Withdrawn
ProcyclidineProcyclidine may increase the anticholinergic activities of Botulinum Toxin Type A.Approved
PropanthelinePropantheline may increase the anticholinergic activities of Botulinum Toxin Type A.Approved
PropiverinePropiverine may increase the anticholinergic activities of Botulinum Toxin Type A.Investigational
PuromycinPuromycin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.Experimental
PyrantelBotulinum Toxin Type A may increase the neuromuscular blocking activities of Pyrantel.Approved, Vet Approved
QuinidineQuinidine may increase the anticholinergic activities of Botulinum Toxin Type A.Approved
RapacuroniumBotulinum Toxin Type A may increase the neuromuscular blocking activities of Rapacuronium.Withdrawn
RibostamycinRibostamycin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.Approved
RocuroniumBotulinum Toxin Type A may increase the neuromuscular blocking activities of Rocuronium.Approved
ScopolamineScopolamine may increase the anticholinergic activities of Botulinum Toxin Type A.Approved
Scopolamine butylbromideScopolamine butylbromide may increase the anticholinergic activities of Botulinum Toxin Type A.Approved
SisomicinSisomicin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.Investigational
SolifenacinSolifenacin may increase the anticholinergic activities of Botulinum Toxin Type A.Approved
SP1049CSP1049C may increase the neuromuscular blocking activities of Botulinum Toxin Type A.Investigational
SpectinomycinSpectinomycin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.Approved, Vet Approved
StreptomycinStreptomycin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.Approved, Vet Approved
StreptozocinStreptozocin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.Approved
SuccinylcholineBotulinum Toxin Type A may increase the neuromuscular blocking activities of Succinylcholine.Approved
TiotropiumTiotropium may increase the anticholinergic activities of Botulinum Toxin Type A.Approved
TobramycinTobramycin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.Approved, Investigational
TolterodineTolterodine may increase the anticholinergic activities of Botulinum Toxin Type A.Approved, Investigational
TrihexyphenidylTrihexyphenidyl may increase the anticholinergic activities of Botulinum Toxin Type A.Approved
TrimethaphanTrimethaphan may increase the anticholinergic activities of Botulinum Toxin Type A.Approved
TropicamideTropicamide may increase the anticholinergic activities of Botulinum Toxin Type A.Approved
TrospiumTrospium may increase the anticholinergic activities of Botulinum Toxin Type A.Approved
TubocurarineBotulinum Toxin Type A may increase the neuromuscular blocking activities of Tubocurarine.Approved
UmeclidiniumUmeclidinium may increase the anticholinergic activities of Botulinum Toxin Type A.Approved
ValrubicinValrubicin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.Approved
VecuroniumBotulinum Toxin Type A may increase the neuromuscular blocking activities of Vecuronium.Approved
ZorubicinZorubicin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.Experimental
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General References
  1. Montecucco C, Molgo J: Botulinal neurotoxins: revival of an old killer. Curr Opin Pharmacol. 2005 Jun;5(3):274-9. [PubMed:15907915 ]
  2. Brin MF, Lew MF, Adler CH, Comella CL, Factor SA, Jankovic J, O'Brien C, Murray JJ, Wallace JD, Willmer-Hulme A, Koller M: Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology. 1999 Oct 22;53(7):1431-8. [PubMed:10534247 ]
  3. Shukla HD, Sharma SK: Clostridium botulinum: a bug with beauty and weapon. Crit Rev Microbiol. 2005;31(1):11-8. [PubMed:15839401 ]
  4. Eisenach JH, Atkinson JL, Fealey RD: Hyperhidrosis: evolving therapies for a well-established phenomenon. Mayo Clin Proc. 2005 May;80(5):657-66. [PubMed:15887434 ]
  5. Schurch B, Corcos J: Botulinum toxin injections for paediatric incontinence. Curr Opin Urol. 2005 Jul;15(4):264-7. [PubMed:15928517 ]
External Links
ATC CodesNot Available
AHFS Codes
  • 92:00.00
PDB Entries
FDA labelDownload (115 KB)
MSDSNot Available
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
0Active Not RecruitingTreatmentBladder Pain Syndrome1
0CompletedTreatmentStroke1
0RecruitingTreatmentNeuralgia1
0WithdrawnDiagnosticBenign Prostatic Hyperplasia (BPH) / Carcinoma of the Prostate / Enlarged Prostate With Lower Urinary Tract Symptoms (LUTS)1
1Active Not RecruitingTreatmentPruritus1
1CompletedNot AvailablePsoriasis Vulgaris1
1CompletedTreatmentBMI >30 kg/m22
1CompletedTreatmentCerebral Palsy (CP) / Spasticity1
1CompletedTreatmentDry Eye Syndromes1
1CompletedTreatmentOsteoarthritis,Knee1
1CompletedTreatmentScrotal Pain1
1CompletedTreatmentVaginismus1
1CompletedTreatmentVasculogenic Erectile Dysfunction1
1CompletedTreatmentWound; Abdomen, Abdominal Wall1
1RecruitingTreatmentBotulinum Toxins, Type A / Plantar Fascitis1
1RecruitingTreatmentCervicalgia / Low Back Pain (LBP)1
1RecruitingTreatmentDepression / Parkinson's Disease (PD)1
1RecruitingTreatmentMyofascial Pain Syndromes / Myofascial Trigger Point Pain / Trigger Point Pain, Myofascial1
1Unknown StatusTreatmentBruxism / Myofascial Pain Dysfunction Syndrome, Temporomandibular Joint / Temporomandibular Joint Disorders / Temporomandibular Joint Dysfunction Syndrome1
1Unknown StatusTreatmentThoracic Outlet Syndrome1
1WithdrawnTreatmentTorticollis1
1, 2Active Not RecruitingTreatmentOral Dystonia / Tardive Dystonia1
1, 2CompletedTreatmentBenign Prostatic Hyperplasia (BPH)1
1, 2CompletedTreatmentCervical Dystonia / Refractory Cervicothoracic Myofascial Pain Syndrome (CMPS)1
1, 2CompletedTreatmentCluster Headache1
1, 2CompletedTreatmentDetrusor Hyperreflexia / Detrusor Instability / Over Active Bladder1
1, 2CompletedTreatmentMigraine Disorders1
1, 2CompletedTreatmentSynovitis of osteoarthritis1
1, 2Not Yet RecruitingTreatmentAbnormal Head Position and Neck Pain for These 7 Muscle Groups: Splenius,Scalene,Sterno-cleido-mastoid,Levator Scapulae,Semispinalis,Trapezius,and Longissimus / Cervical Dystonia Adults 1
1, 2Not Yet RecruitingTreatmentChronic Migraine More than15 Days Per Month, and Lasting 4 Hours a Day or Longer1
1, 2Not Yet RecruitingTreatmentCluster Headache1
1, 2Not Yet RecruitingTreatmentIncreased Muscle Tone in Elbow, Wrist, Finger, and Thumb Flexors / Upper Limb Spasticity Unilaterally in Adults With History of Stroke1
1, 2RecruitingPreventionNonvalvular Atrial Fibrillation1
1, 2RecruitingTreatmentCleft Lip / Cleft Palates / Scarring1
1, 2RecruitingTreatmentHeadache Disorders / Trigeminal Neuralgia1
1, 2TerminatedTreatmentEmpty Nose Syndrome / Rhinitis, Atrophic1
1, 2Unknown StatusTreatmentUrge Urinary Incontinence1
2Active Not RecruitingTreatmentCarpal Tunnel Syndrome (CTS)1
2Active Not RecruitingTreatmentLow Anterior Resection Syndrome / Rectal Cancers1
2Active Not RecruitingTreatmentMasticatory Muscles, Hypertrophy of1
2Active Not RecruitingTreatmentObesity, Morbid1
2Active Not RecruitingTreatmentRaynaud's Disease1
2CompletedPreventionMigraines1
2CompletedTreatmentAmyotrophic Lateral Sclerosis (ALS) / Sialorrhea1
2CompletedTreatmentAnal Fissures1
2CompletedTreatmentBenign Prostatic Hyperplasia (BPH)3
2CompletedTreatmentBlepharospasm1
2CompletedTreatmentBotulinum Toxins, Type A1
2CompletedTreatmentBurning Mouth Syndrome1
2CompletedTreatmentCerebral Palsy (CP)1
2CompletedTreatmentCerebral Palsy (CP) / Equine and Equinovarus Foot Deformation / Spastic Paraplegia and Hemiparesis1
2CompletedTreatmentCerebral Palsy (CP) / Muscle Spasticity1
2CompletedTreatmentCervical Dystonia2
2CompletedTreatmentCervicogenic Headaches1
2CompletedTreatmentChronic Pain Syndrome / Prostatitis1
2CompletedTreatmentContractures / Muscle Spasticity / Stroke1
2CompletedTreatmentCrows Feet / Facial Wrinkles / Lateral Canthal Lines3
2CompletedTreatmentCrows Feet / Lateral Canthal Lines1
2CompletedTreatmentCutaneous Leiomyomas / Hereditary Leiomyomatosis and Renal Cell Cancer1
2CompletedTreatmentDementias / Paratonia1
2CompletedTreatmentDepression2
2CompletedTreatmentDetrusor Muscle Hyperactivity1
2CompletedTreatmentEpiphora1
2CompletedTreatmentEssential Tremor of the Upper Limbs1
2CompletedTreatmentFacial Rhytids1
2CompletedTreatmentGlabellar Frown Lines3
2CompletedTreatmentHyperhidrosis1
2CompletedTreatmentInterstitial Cystitis1
2CompletedTreatmentLateral Canthal Lines1
2CompletedTreatmentMajor Depressive Disorder (MDD)1
2CompletedTreatmentMotor Neuron Disease / Muscle Spasticity / Stroke1
2CompletedTreatmentMuscle Spasticity / Stroke2
2CompletedTreatmentMyofascial Pain Syndromes2
2CompletedTreatmentOver Active Bladder3
2CompletedTreatmentOver Active Bladder / Urinary Incontinence (UI)1
2CompletedTreatmentPain of the knee1
2CompletedTreatmentParkinson / Tremors1
2CompletedTreatmentPostherpetic Neuralgia1
2CompletedTreatmentProctalgia1
2CompletedTreatmentRestless Legs Syndrome (RLS)1
2CompletedTreatmentSialorrhea1
2CompletedTreatmentSkin Aging1
2CompletedTreatmentStomach Neoplasms1
2CompletedTreatmentThoracic Outlet Syndrome1
2CompletedTreatmentSynovitis of osteoarthritis1
2Enrolling by InvitationPreventionPost-operative Excessive Scarring1
2Enrolling by InvitationTreatmentScrotal Pain1
2Enrolling by InvitationTreatmentTremors1
2Not Yet RecruitingTreatmentRotator Cuff Tear Arthropathy1
2Not Yet RecruitingTreatmentTemporo-Myofascial Disorder1
2RecruitingSupportive CareEsophageal Carcinoma1
2RecruitingTreatmentAtrial Flutter1
2RecruitingTreatmentBenign Prostatic Hyperplasia (BPH) / Lower Urinary Track Symptoms1
2RecruitingTreatmentBladder Pain Syndrome1
2RecruitingTreatmentBorderline Personality Disorder (BPD)1
2RecruitingTreatmentCerebral Palsy, Spastic / Pain1
2RecruitingTreatmentCervical Dystonia1
2RecruitingTreatmentChronic Diseases / Nasal Polyposis / Rhinitis1
2RecruitingTreatmentChronic Testicular Pain1
2RecruitingTreatmentDystonias1
2RecruitingTreatmentEssential Tremor1
2RecruitingTreatmentHyperhidrosis1
2RecruitingTreatmentHypertrophy of Masseter Muscle1
2RecruitingTreatmentMigraine Disorders / Migraine Headaches / Pediatrics1
2RecruitingTreatmentNeuropathic Back Pain / Spinal Cord Injuries (SCI)1
2RecruitingTreatmentObstructed Defecation Syndrome (ODS)1
2RecruitingTreatmentParkinson's Disease (PD)1
2RecruitingTreatmentPeyronie's Disease1
2RecruitingTreatmentPost-Operative Pain1
2RecruitingTreatmentPremature Ejaculation1
2RecruitingTreatmentTrigeminal Neuralgia1
2TerminatedTreatmentAcne Vulgaris1
2TerminatedTreatmentAllodynia / Pain, Neuropathic1
2TerminatedTreatmentBlepharospasm1
2TerminatedTreatmentCerebral Palsy (CP)1
2TerminatedTreatmentHabitual Snoring1
2TerminatedTreatmentLower Back Pain1
2TerminatedTreatmentNeurogenic Bladder Dysfunction Nos / Spinal Cord Injuries (SCI)1
2TerminatedTreatmentNew Daily Persistent Headache1
2TerminatedTreatmentOver Active Bladder2
2TerminatedTreatmentPain1
2Unknown StatusPreventionScarring1
2Unknown StatusTreatmentArthritis / Pain1
2Unknown StatusTreatmentEpidermolysis Bullosa Simplex1
2Unknown StatusTreatmentHemifacial Spasm1
2Unknown StatusTreatmentRosaceas1
2WithdrawnTreatmentAmyotrophic Lateral Sclerosis (ALS) / Parkinson's Disease (PD)1
2WithdrawnTreatmentCarcinoma of the Prostate / Lower Urinary Tract Symptoms (LUTS) / Radioactive Seed Implantation1
2WithdrawnTreatmentContact Ulcer of Vocal Folds / Granuloma / Granuloma of Vocal Cords / Granuloma, Laryngeal1
2WithdrawnTreatmentNeuroma1
2WithdrawnTreatmentOver Active Bladder / Urinary Incontinence (UI)1
2, 3CompletedTreatmentBenign Prostatic Enlargement (BPE) / Benign Prostatic Hyperplasia (BPH)1
2, 3CompletedTreatmentChronic Plantar Fasciitis1
2, 3CompletedTreatmentFowler's Syndrome / Urinary Retention1
2, 3CompletedTreatmentRecalcitrant Alopecia Totalis / Recalcitrant Alopecia Universalis1
2, 3CompletedTreatmentRefractory Migraine1
2, 3CompletedTreatmentSialorrhea1
2, 3RecruitingPreventionScarring1
2, 3RecruitingTreatmentBlepharospasm1
2, 3RecruitingTreatmentCrows Feet Lines1
2, 3RecruitingTreatmentErectile Dysfunction (ED) / Sexual Dysfunctions1
2, 3TerminatedTreatmentPrimary Focal Hyperhidrosis of the Hands1
2, 3Unknown StatusPreventionForward Head Posture With Associated Episodic Headache Disorder1
2, 3Unknown StatusTreatmentCerebral Palsy (CP) / Sialorrhea1
2, 3Unknown StatusTreatmentLower Limb Spasticity After Stroke1
2, 3Unknown StatusTreatmentNon-relaxing Puborectalis Syndrome1
2, 3Unknown StatusTreatmentOver Active Bladder1
3Active Not RecruitingTreatmentGlabellar Lines1
3Active Not RecruitingTreatmentStroke1
3CompletedNot AvailableAging1
3CompletedSupportive CareStroke With Hemiparesis1
3CompletedTreatmentAllodynia / Headaches1
3CompletedTreatmentBilateral Blepharospasm (BEB)1
3CompletedTreatmentBlepharospasm2
3CompletedTreatmentCanthal Lines1
3CompletedTreatmentCerebral Palsy (CP) / Children / Muscle Spasticity2
3CompletedTreatmentCerebrovascular Accidents3
3CompletedTreatmentCervical Dystonia5
3CompletedTreatmentChronic Troublesome Sialorrhea / Parkinson's Disease (PD) / Post-stroke / Traumatic Brain Injury (TBI)1
3CompletedTreatmentCrow's Feet Lines / Facial Rhytides / Glabellar Lines2
3CompletedTreatmentCrow's Feet Lines / Frown Lines / Glabellar Lines / Upper Facial Rhytides1
3CompletedTreatmentCrow's Feet Lines / Lateral Canthal Lines1
3CompletedTreatmentCrow's Feet Lines / Lateral Canthus Rhytides2
3CompletedTreatmentEssential Blepharospasm1
3CompletedTreatmentFacial Rhytides / Glabellar Rhytides1
3CompletedTreatmentForehead Rhytides / Glabellar Rhytides1
3CompletedTreatmentFrown Lines Between the Eyebrows / Glabellar Rhytides1
3CompletedTreatmentGlabellar Frown Lines1
3CompletedTreatmentGlabellar Lines3
3CompletedTreatmentGlabellar Rhytides2
3CompletedTreatmentHyperhidrosis1
3CompletedTreatmentLateral Periorbital Wrinkles1
3CompletedTreatmentLeg Spasticity1
3CompletedTreatmentLow Back Pain (LBP)1
3CompletedTreatmentLower Extremity Deformities, Congenital / Unequal Length of Limbs; Congenital1
3CompletedTreatmentLower Limb Spasticity Due to Cerebral Palsy1
3CompletedTreatmentLower Limb and Combined Lower Limb and Upper Limb Spasticity Due to Cerebral Palsy1
3CompletedTreatmentMigraine Disorders3
3CompletedTreatmentModerate to Severe Glabellar Line1
3CompletedTreatmentMultiple Sclerosis (MS) / Neurogenic Bladder / Urinary Incontinence (UI)1
3CompletedTreatmentMultiple Sclerosis (MS) / Tremors1
3CompletedTreatmentMuscle Spasticity1
3CompletedTreatmentMyofascial Pain Syndromes1
3CompletedTreatmentNervous System Disorders2
3CompletedTreatmentNeurogenic Detrusor Overactivity1
3CompletedTreatmentNotalgia Paresthetica1
3CompletedTreatmentOther Infantile Cerebral Palsy1
3CompletedTreatmentOver Active Bladder5
3CompletedTreatmentOver Active Bladder / Urinary Incontinence (UI)2
3CompletedTreatmentPost-stroke Spasticity of the Lower Limb1
3CompletedTreatmentPost-stroke Spasticity of the Upper Limb1
3CompletedTreatmentPost-stroke Upper Limb Spasticity1
3CompletedTreatmentRaynaud's Syndrome / Scleroderma1
3CompletedTreatmentRefractory Urge Urinary Incontinence / Urinary Incontinence, Urge1
3CompletedTreatmentSkin Aging5
3CompletedTreatmentSpasticity1
3CompletedTreatmentSpasticity Post-Traumatic Brain Injury / Spasticity, Post-Stroke1
3CompletedTreatmentSpasticity of the Upper and Lower Limb Due to Cerebral Causes1
3CompletedTreatmentSpasticity, Post-Stroke1
3CompletedTreatmentSpasticity / Stroke2
3CompletedTreatmentStrabismus1
3CompletedTreatmentTennis Elbow1
3CompletedTreatmentUpper Limb Spasticity1
3CompletedTreatmentFacial fine wrinkling1
3Enrolling by InvitationTreatmentChronic Migraine1
3Enrolling by InvitationTreatmentOver Active Bladder1
3Not Yet RecruitingTreatmentCerebrovascular Accidents1
3Not Yet RecruitingTreatmentVulvodynia1
3RecruitingSupportive CareBRCA1 Mutations / BRCA2 Mutation / Breast Diseases / Cancer, Breast / Neoplasms / Postoperative Pain1
3RecruitingTreatmentCOMPARISON BETWEEN GROUP TREATED WITH BOTULINUM TOXIN AND PLACEBO1
3RecruitingTreatmentCerebral Palsy (CP) / Chronic Troublesome Sialorrhea / Intellectual Disability / Stroke / Traumatic Brain Injury (TBI)1
3RecruitingTreatmentCerebral Palsy (CP) / Muscle Spasticity / Pediatrics2
3RecruitingTreatmentCerebral Palsy (CP) / Muscle Spasticity / Pediatrics / Stroke2
3RecruitingTreatmentCerebral Palsy (CP) / Spasticity1
3RecruitingTreatmentCerebrovascular Accidents1
3RecruitingTreatmentLower Urinary Tract Discomfort / Stent Pain1
3RecruitingTreatmentOver Active Bladder1
3RecruitingTreatmentOver Active Bladder / Urinary Incontinence (UI)2
3RecruitingTreatmentStroke1
3RecruitingTreatmentTennis Elbow1
3RecruitingTreatmentUpper Limb Spasticity (Altered Skeletal Muscle Performance) in Children1
3RecruitingTreatmentUrinary Bladder, Overactive / Urinary Incontinence (UI)1
3RecruitingTreatmentUrinary Incontinence (UI)2
3RecruitingTreatmentVestibulodynia1
3TerminatedTreatmentChronic Post Traumatic Headache1
3TerminatedTreatmentChronic Prostatitis With Chronic Pelvic Pain Syndrome / Prostatitis1
3TerminatedTreatmentDetrusor Hyperreflexia / Over Active Bladder / Urge Incontinence / Urinary Incontinence (UI) / Urinary Urge Incontinence1
3TerminatedTreatmentDetrusor Overactivity / Urge Urinary Incontinence / Urinary Incontinence (UI) / Urination urgency of1
3TerminatedTreatmentMuscle Spasticity / Stroke1
3TerminatedTreatmentOver Active Bladder1
3TerminatedTreatmentPatellofemoral Pain Syndrome1
3TerminatedTreatmentSkin Aging1
3Unknown StatusTreatmentHemiplegic Patients Post-AVC1
3Unknown StatusTreatmentOver Active Bladder1
3Unknown StatusTreatmentScarring1
3Unknown StatusTreatmentFacial fine wrinkling1
3WithdrawnNot AvailableNeuralgia / Pain Due to Certain Specified Procedures / Pain, Neuropathic1
3WithdrawnTreatmentMuscle Spasticity / Stroke1
4Active Not RecruitingPreventionMigraine Disorders1
4Active Not RecruitingTreatmentChronic Idiopathic Constipation / Functional Constipation1
4Active Not RecruitingTreatmentOver Active Bladder1
4Active Not RecruitingTreatmentParkinson's Disease (PD)1
4CompletedNot AvailableHealthy Subjects, Only With Wrinkles on Forehead1
4CompletedNot AvailableMigraine Disorders1
4CompletedNot AvailableUrinary Bladder, Overactive1
4CompletedPreventionStroke / Upper Limb Spasticity1
4CompletedTreatmentAging1
4CompletedTreatmentBlepharospasm1
4CompletedTreatmentBrain Injury / Spasticity Secondary to Either a Disorder or Trauma / Spinal Cord Injuries (SCI) / Stroke / Tumors1
4CompletedTreatmentBrain Injury / Spasticity / Stroke1
4CompletedTreatmentBrow Ptosis1
4CompletedTreatmentBrow Ptosis / Lid Ptosis1
4CompletedTreatmentCerebral Palsy (CP)1
4CompletedTreatmentCerebral Palsy and Botulinum Toxin1
4CompletedTreatmentCerebrovascular Accidents / Muscle Spasticity2
4CompletedTreatmentCervical Dystonia4
4CompletedTreatmentChronic Migraine5
4CompletedTreatmentCrow's Feet Lines / Facial Rhytides / Glabellar Lines / Nasolabial Folds1
4CompletedTreatmentDiabetic Polyneuropathies / Other Polyneuropathies / Postherpetic Neuralgia1
4CompletedTreatmentEsotropia / Exotropia1
4CompletedTreatmentEssential Blepharospasm1
4CompletedTreatmentFacial Asymmetry / Facial Nerve Injuries / Facial Paresis Associated With Facial Nerve Dysfunction / Synkinesis1
4CompletedTreatmentFacial Rhytides1
4CompletedTreatmentGlabellar Frown Lines3
4CompletedTreatmentGlabellar Furrows1
4CompletedTreatmentGlabellar Lines1
4CompletedTreatmentGlabellar Rhytides1
4CompletedTreatmentHallux Valgus1
4CompletedTreatmentHyperhidrosis2
4CompletedTreatmentInterstitial Cystitis / Painful Bladder Syndrome (PBS)1
4CompletedTreatmentIntrinsic Aging of Skin / Solar Elastosis1
4CompletedTreatmentMigraine Disorders2
4CompletedTreatmentMild to Moderate Temporal Atrophy / Moderate to Severe Glabellar Rhytids / Moderate to Severe Periorbital Rhytids1
4CompletedTreatmentMultiple Sclerosis (MS) / Muscle Spasticity1
4CompletedTreatmentMuscle Spasticity1
4CompletedTreatmentOver Active Bladder / Urinary Incontinence (UI)1
4CompletedTreatmentPain, Neuropathic / Spinal Cord Injuries (SCI)1
4CompletedTreatmentPlantar Fascitis1
4CompletedTreatmentSkin Aging1
4CompletedTreatmentSpasmodic Torticollis1
4CompletedTreatmentSpasticity1
4CompletedTreatmentSun-induced Wrinkles1
4CompletedTreatmentTorticollis1
4CompletedTreatmentUpper Limb Spasticity1
4CompletedTreatmentWrinkles in Frontal Area1
4CompletedTreatmentFacial fine wrinkling1
4Enrolling by InvitationPreventionOver Active Bladder / Painful Bladder Syndrome (PBS) / Urinary Bladder, Neurogenic / Urinary Urge Incontinence1
4Not Yet RecruitingTreatmentActivity / Pain1
4RecruitingNot AvailableCrow's Feet Lines / Lateral Canthal Lines1
4RecruitingPreventionOther Degenerative Disorders of Eyelid and Periocular Area1
4RecruitingTreatmentAnxiety / Anxiety Disorder Social1
4RecruitingTreatmentBreast Diseases / Neoplasms / Neoplasms by Site / Neoplasms, Breast / Skin Diseases1
4RecruitingTreatmentBrow Lifting1
4RecruitingTreatmentCerebral Palsy (CP) / Muscle Spasticity1
4RecruitingTreatmentInterstitial Cystitis1
4RecruitingTreatmentMixed Urinary Incontinence / Stress Urinary Incontinence (SUI) / Urgency Incontinence1
4RecruitingTreatmentOsteoarthritis,Knee1
4RecruitingTreatmentSpastic Hemiparesis1
4RecruitingTreatmentSpinal Cord Injuries (SCI) / Urinary Bladder, Overactive1
4RecruitingTreatmentStroke Rehabilitation / Stroke Rehabilitation Spasticity Management1
4RecruitingTreatmentUrinary Bladder, Overactive / Urinary Incontinence (UI)1
4TerminatedTreatmentArthritis Multiple Joint / Basal Thumb Joint Arthritis / Basilar Joint Arthritis / Carpometacarpal Arthritis / Trapeziometacarpal Arthritis1
4TerminatedTreatmentChronic Male Pelvic Pain Syndrome1
4TerminatedTreatmentLow Back Pain (LBP)1
4TerminatedTreatmentParkinson's Disease (PD)1
4TerminatedTreatmentSpasmodic Torticollis1
4Unknown StatusPreventionAutonomic Dysreflexia1
4Unknown StatusTreatmentBruxism1
4Unknown StatusTreatmentCatocholamine Induced Finger Necrosis1
4Unknown StatusTreatmentChronic Low Back Pain (CLBP)1
4Unknown StatusTreatmentElastosis Senilis / Skin Aging1
4Unknown StatusTreatmentMajor Depressive Disorder (MDD)1
4Unknown StatusTreatmentMuscle Spasticity1
4Unknown StatusTreatmentOveractive Detrusor1
4Unknown StatusTreatmentScarring1
4Unknown StatusTreatmentSleep Bruxism1
4WithdrawnTreatmentFoot Deformities / Leg Length Inequality1
4WithdrawnTreatmentGraves Ophthalmopathy1
Not AvailableActive Not RecruitingNot AvailableDetrusor, Overactive / Lower Urinary Tract Symptoms (LUTS) / Multiple Sclerosis (MS) / Neurogenic Bladder / Urge Incontinence1
Not AvailableActive Not RecruitingNot AvailableLower Limb Spasticity1
Not AvailableActive Not RecruitingNot AvailableMuscle Spasticity1
Not AvailableActive Not RecruitingTreatmentFacial Flushing1
Not AvailableActive Not RecruitingTreatmentHeadaches1
Not AvailableActive Not RecruitingTreatmentIdiopathic Clubfoot (Talipes Equinovarus)2
Not AvailableActive Not RecruitingTreatmentFacial fine wrinkling1
Not AvailableCompletedNot AvailableBlepharospasm / Cervical Dystonia1
Not AvailableCompletedNot AvailableChronic Migraine, Headaches1
Not AvailableCompletedNot AvailableFacial Rhytides1
Not AvailableCompletedNot AvailableGlabellar Lines1
Not AvailableCompletedNot AvailableGlabellar Lines / Hyperhidrosis / Muscle Spasticity1
Not AvailableCompletedNot AvailableHeadaches / Migraine Disorders1
Not AvailableCompletedNot AvailableMigraine Disorders1
Not AvailableCompletedNot AvailableMumps1
Not AvailableCompletedNot AvailableMuscle Spasticity1
Not AvailableCompletedNot AvailableSkin Laxity1
Not AvailableCompletedNot AvailableSpasticity, Post-Stroke1
Not AvailableCompletedNot AvailableTorticollis1
Not AvailableCompletedNot AvailableUrinary Bladder, Neurogenic / Urinary Bladder, Overactive1
Not AvailableCompletedNot AvailableUrinary Bladder, Overactive / Urinary Incontinence (UI)2
Not AvailableCompletedNot AvailableUrinary Incontinence (UI)1
Not AvailableCompletedDiagnosticBotulinum Toxins, Type A / Normal, Healthy Volunteers / Strength, Muscle1
Not AvailableCompletedHealth Services ResearchHealthy Volunteers1
Not AvailableCompletedHealth Services ResearchMuscle Spasticity / Stroke1
Not AvailableCompletedPreventionHerpes Labialis1
Not AvailableCompletedPreventionPost Traumatic Stiffness1
Not AvailableCompletedSupportive CarePain1
Not AvailableCompletedTreatmentAchalasia, Esophageal1
Not AvailableCompletedTreatmentAxillary Hyperhidrosis1
Not AvailableCompletedTreatmentCerebral Palsy (CP) / Muscle Spasticity1
Not AvailableCompletedTreatmentDiabetes Mellitus (DM) / Pain, Neuropathic1
Not AvailableCompletedTreatmentDiabetes Mellitus (DM) / Peripheral Neuropathy / Plantar Ulcers1
Not AvailableCompletedTreatmentEpicondylitis, Lateral Humeral / Tennis Elbow1
Not AvailableCompletedTreatmentEssential Tremor1
Not AvailableCompletedTreatmentFacial Paralysis1
Not AvailableCompletedTreatmentFacial Rhytides / Glabellar Frown Lines1
Not AvailableCompletedTreatmentFacial Wrinkles1
Not AvailableCompletedTreatmentHIV Posterior Cheek Enlargement1
Not AvailableCompletedTreatmentHyperhidrosis1
Not AvailableCompletedTreatmentKeratoconus1
Not AvailableCompletedTreatmentNon-neurogenic / Urinary Urge Incontinence1
Not AvailableCompletedTreatmentPost-stroke Shoulder Pain and Spasticity1
Not AvailableCompletedTreatmentPrimary Axillary Hyperhidrosis1
Not AvailableCompletedTreatmentRaynaud's Syndrome1
Not AvailableCompletedTreatmentSkin Wrinklings1
Not AvailableCompletedTreatmentSpastic Equinovarus1
Not AvailableCompletedTreatmentSubacute Cervical Pain / Subacute Upper Back Pain1
Not AvailableCompletedTreatmentUrinary Incontinence (UI)1
Not AvailableCompletedTreatmentVaginismus1
Not AvailableNot Yet RecruitingNot AvailableUrinary Bladder, Overactive1
Not AvailableRecruitingNot AvailableEsthetic Outcome of Injection of Botulinum Toxin Type-A in Cleft Lip Repair1
Not AvailableRecruitingNot AvailableLower Limb Spasticity1
Not AvailableRecruitingNot AvailableMixed Incontinence, Urge and Stress1
Not AvailableRecruitingNot AvailableOver Active Bladder / Urinary Incontinence (UI)1
Not AvailableRecruitingTreatmentChronic Vocal Tic / Tourette's Syndrome1
Not AvailableRecruitingTreatmentEpicondylitis, Lateral Humeral / Tennis Elbow1
Not AvailableRecruitingTreatmentMigraine Headaches1
Not AvailableRecruitingTreatmentMyofascial Pelvic Pain1
Not AvailableRecruitingTreatmentPelvic Pain1
Not AvailableRecruitingTreatmentPlantar fascial fibromatosis1
Not AvailableSuspendedTreatmentPain1
Not AvailableTerminatedNot AvailableCerebral Palsy (CP)1
Not AvailableTerminatedTreatmentBrain Injury / Stiff Knee Gait1
Not AvailableTerminatedTreatmentEquinus Contracture1
Not AvailableTerminatedTreatmentIschaemia / Vasopressor1
Not AvailableTerminatedTreatmentMigraine Headaches1
Not AvailableUnknown StatusTreatmentAlopecia Areata (AA)1
Not AvailableUnknown StatusTreatmentEsophageal Spasm, Diffuse1
Not AvailableUnknown StatusTreatmentFlexion Contracture Following Total Knee Replacement1
Not AvailableUnknown StatusTreatmentPain1
Not AvailableUnknown StatusTreatmentTennis Elbow / Type A Botulinum Toxin1
Not AvailableWithdrawnNot AvailableChronic Migraine, Headaches1
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Injection, powder, lyophilized, for solutionIntradermal; Intramuscular100 [USP'U]/1
Injection, powder, lyophilized, for solutionIntradermal; Intramuscular200 [USP'U]/1
Powder, for solutionIntramuscular100 unit
Injection, powder, lyophilized, for solutionIntramuscular300 U/1
Injection, powder, lyophilized, for solutionIntramuscular500 U/1
Powder, for solutionIntramuscular300 unit
Powder, for solutionIntramuscular500 unit
Injection, powder, lyophilized, for solutionIntramuscular100 [USP'U]/1
Injection, powder, lyophilized, for solutionIntramuscular200 [USP'U]/1
Injection, powder, lyophilized, for solutionIntramuscular50 [USP'U]/1
Powder, for solutionIntramuscular50 unit
Prices
Unit descriptionCostUnit
Botox 200 unit vial1260.0USD vial
Dysport 500 unit vial852.0USD vial
Botox 100 unit655.2USD vial
Botox 100 unit vial630.0USD vial
Botox cosmetic 100 unit vial630.0USD vial
Botox cosmetic 50 unit vial346.8USD vial
Botox (100 - 200 unit/Vial)3.74USD vial
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2280565 No2005-11-152019-08-20Canada
CA2310845 No2001-05-152014-06-07Canada
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilitySolubleNot Available
hydrophobicity-0.368Not Available
isoelectric point6.06Not Available
Taxonomy
DescriptionNot Available
KingdomOrganic Compounds
Super ClassOrganic Acids
ClassCarboxylic Acids and Derivatives
Sub ClassAmino Acids, Peptides, and Analogues
Direct ParentPeptides
Alternative ParentsNot Available
SubstituentsNot Available
Molecular FrameworkNot Available
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Syntaxin-1 binding
Specific Function:
t-SNARE involved in the molecular regulation of neurotransmitter release. May play an important role in the synaptic function of specific neuronal systems. Associates with proteins involved in vesicle docking and membrane fusion. Regulates plasma membrane recycling through its interaction with CENPF. Modulates the gating characteristics of the delayed rectifier voltage-dependent potassium chann...
Gene Name:
SNAP25
Uniprot ID:
P60880
Molecular Weight:
23314.905 Da
References
  1. Zhou JY, Wang ZF, Ren XM, Tang MZ, Shi YL: Antagonism of botulinum toxin type A-induced cleavage of SNAP-25 in rat cerebral synaptosome by toosendanin. FEBS Lett. 2003 Dec 4;555(2):375-9. [PubMed:14644446 ]
  2. Flynn TC: Myobloc. Dermatol Clin. 2004 Apr;22(2):207-11, vii. [PubMed:15222581 ]
  3. Okada M, Yoshida S, Zhu G, Kaneko S: [Methodological consideration in studying the exocytosis mechanisms using microdialysis]. Nihon Shinkei Seishin Yakurigaku Zasshi. 2004 Aug;24(4):165-70. [PubMed:15484814 ]
  4. Frassoni C, Inverardi F, Coco S, Ortino B, Grumelli C, Pozzi D, Verderio C, Matteoli M: Analysis of SNAP-25 immunoreactivity in hippocampal inhibitory neurons during development in culture and in situ. Neuroscience. 2005;131(4):813-23. [PubMed:15749336 ]
  5. Straughan D: Progress in applying the Three Rs to the potency testing of Botulinum toxin type A. Altern Lab Anim. 2006 Jun;34(3):305-13. [PubMed:16831062 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Gtpase activity
Specific Function:
Mediates apoptosis in neoplastically transformed cells after DNA damage. Not essential for development but affects cell adhesion and growth factor signaling in transformed cells. Plays a negative role in tumorigenesis as deletion causes tumor formation. Involved in intracellular protein trafficking of a number of proteins. Targets PKN1 to endosomes and is involved in trafficking of the EGF rece...
Gene Name:
RHOB
Uniprot ID:
P62745
Molecular Weight:
22123.185 Da
References
  1. Ishida H, Zhang X, Erickson K, Ray P: Botulinum toxin type A targets RhoB to inhibit lysophosphatidic acid-stimulated actin reorganization and acetylcholine release in nerve growth factor-treated PC12 cells. J Pharmacol Exp Ther. 2004 Sep;310(3):881-9. Epub 2004 May 12. [PubMed:15140914 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23